本报道最初发表于Endpoints News。请点击这里查看原文
A small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug candidate into human trials, Amgen eventually discarded those plans and gave the TCE back to its creator.
一家小型加州初创公司正在重新开发一种实验性T细胞连接子(TCE)，这一药物最初由该公司科学家研发，但多年前转交给安进(Amgen)。安进曾多次表示将把这一候选药物推进到人体试验阶段，但最终放弃了相关计划，并将这款T细胞连接子归还给最初的开发方。
您已阅读7%（457字），剩余93%（6090字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。